Mariana Esteves1, Sofia Lopes1, Filomena Azevedo1, Ana Pedrosa1,2. 1. Serviço de Dermatologia e Venereologia, Centro Hospitalar Universitário de São João EPE, Porto, Portugal. 2. Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
Abstract
INTRODUCTION: Alopecia areata (AA) is a form of nonscarring alopecia and one of the most common autoimmune disorders. Persistent or severe variants lead to potential disfigurement and are associated with a significant negative impact on the patient's quality of life. CASE PRESENTATION: A 51-year-old female patient presenting with refractory alopecia universalis was successfully treated with oral tofacitinib. Recurrence was not observed following 17 months of therapy. DISCUSSION/ CONCLUSION: None of the currently employed therapies for AA are reliably effective nor are they approved for the disease. In this setting, Janus kinase inhibitors emerge as a promising novel treatment, as increasing evidence supports their effectiveness in AA.
INTRODUCTION: Alopecia areata (AA) is a form of nonscarring alopecia and one of the most common autoimmune disorders. Persistent or severe variants lead to potential disfigurement and are associated with a significant negative impact on the patient's quality of life. CASE PRESENTATION: A 51-year-old female patient presenting with refractory alopecia universalis was successfully treated with oral tofacitinib. Recurrence was not observed following 17 months of therapy. DISCUSSION/ CONCLUSION: None of the currently employed therapies for AA are reliably effective nor are they approved for the disease. In this setting, Janus kinase inhibitors emerge as a promising novel treatment, as increasing evidence supports their effectiveness in AA.
Authors: Milène Kennedy Crispin; Justin M Ko; Brittany G Craiglow; Shufeng Li; Gautam Shankar; Jennifer R Urban; James C Chen; Jane E Cerise; Ali Jabbari; Mårten Cg Winge; M Peter Marinkovich; Angela M Christiano; Anthony E Oro; Brett A King Journal: JCI Insight Date: 2016-09-22
Authors: A Jabbari; F Sansaricq; J Cerise; J C Chen; A Bitterman; G Ulerio; J Borbon; R Clynes; A M Christiano; J Mackay-Wiggan Journal: J Invest Dermatol Date: 2018-02-13 Impact factor: 8.551